

CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY

Corey A. Siegel

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

In the LUCENT-2 maintenance trial, mirikizumab-treated patients with moderately to severely active ulcerative colitis who were on corticosteroids at baseline achieved significantly higher rates of corticosteroid-free clinical remission at 52 weeks compared to placebo.

KEY POINTS

- Among patients on corticosteroids at baseline (median dose 20 mg/day), 41.6% of mirikizumab-treated patients achieved clinical remission while off corticosteroids at Week 52 versus 15.3% of placebo patients (risk difference 22.3%, $p=0.002$).
- A significantly greater proportion of mirikizumab patients permanently discontinued corticosteroids by Week 52 compared to placebo (79.2% vs 44.1%, $p<0.001$), with similar differences observed at Weeks 24 and 40.
- Among mirikizumab treatment completers at Week 52, 95.2% had discontinued corticosteroids versus 86.7% of placebo completers.
- All patients entering LUCENT-2 maintenance followed a standardized corticosteroid taper protocol; patients who discontinued study treatment or received rescue treatment were considered treatment failures for corticosteroid discontinuation endpoints.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/2bd4b5a4-743c-11ee-ac52-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.